High Clinical Burden of Influenza Disease in Adults Aged ≥ 65 Years : Can We Do Better? A Systematic Literature Review
© 2023. Pfizer Inc..
INTRODUCTION: Influenza is a respiratory infection associated with a significant clinical burden globally. Adults aged ≥ 65 years are at increased risk of severe influenza-related symptoms and complications due to chronic comorbidity and immunosenescence. Annual influenza vaccination is recommended; however, current influenza vaccines confer suboptimal protection, in part due to antigen mismatch and poor durability. This systematic literature review characterizes the global clinical burden of seasonal influenza among adults aged ≥ 65 years.
METHODS: An electronic database search was conducted and supplemented with a conference abstract search. Included studies described clinical outcomes in the ≥ 65 years population across several global regions and were published in English between January 1, 2012 and February 9, 2022.
RESULTS: Ninety-nine publications were included (accounting for > 156,198,287 total participants globally). Clinical burden was evident across regions, with most studies conducted in the USA and Europe. Risk of influenza-associated hospitalization increased with age, particularly in those aged ≥ 65 years living in long-term care facilities, with underlying comorbidities, and infected with A(H3N2) strains. Seasons dominated by circulating A(H3N2) strains saw increased risk of influenza-associated hospitalization, intensive care unit admission, and mortality within the ≥ 65 years population. Seasonal differences in clinical burden were linked to differences in circulating strains.
CONCLUSIONS: Influenza exerts a considerable burden on adults aged ≥ 65 years and healthcare systems, with high incidence of hospitalization and mortality. Substantial influenza-associated clinical burden persists despite increasing vaccination coverage among adults aged ≥ 65 years across regions included in this review, which suggests limited effectiveness of currently available seasonal influenza vaccines. To reduce influenza-associated clinical burden, influenza vaccine effectiveness must be improved. Next generation vaccine production using mRNA technology has demonstrated high effectiveness against another respiratory virus-SARS-CoV-2-and may overcome the practical limitations associated with traditional influenza vaccine production.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Advances in therapy - 40(2023), 4 vom: 15. Apr., Seite 1601-1627 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Langer, Jakob [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Burden of disease |
|---|
| Anmerkungen: |
Date Completed 05.04.2023 Date Revised 03.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12325-023-02432-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352972467 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352972467 | ||
| 003 | DE-627 | ||
| 005 | 20231226054931.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12325-023-02432-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1176.xml |
| 035 | |a (DE-627)NLM352972467 | ||
| 035 | |a (NLM)36790682 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Langer, Jakob |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High Clinical Burden of Influenza Disease in Adults Aged ≥ 65 Years |b Can We Do Better? A Systematic Literature Review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.04.2023 | ||
| 500 | |a Date Revised 03.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. Pfizer Inc. | ||
| 520 | |a INTRODUCTION: Influenza is a respiratory infection associated with a significant clinical burden globally. Adults aged ≥ 65 years are at increased risk of severe influenza-related symptoms and complications due to chronic comorbidity and immunosenescence. Annual influenza vaccination is recommended; however, current influenza vaccines confer suboptimal protection, in part due to antigen mismatch and poor durability. This systematic literature review characterizes the global clinical burden of seasonal influenza among adults aged ≥ 65 years | ||
| 520 | |a METHODS: An electronic database search was conducted and supplemented with a conference abstract search. Included studies described clinical outcomes in the ≥ 65 years population across several global regions and were published in English between January 1, 2012 and February 9, 2022 | ||
| 520 | |a RESULTS: Ninety-nine publications were included (accounting for > 156,198,287 total participants globally). Clinical burden was evident across regions, with most studies conducted in the USA and Europe. Risk of influenza-associated hospitalization increased with age, particularly in those aged ≥ 65 years living in long-term care facilities, with underlying comorbidities, and infected with A(H3N2) strains. Seasons dominated by circulating A(H3N2) strains saw increased risk of influenza-associated hospitalization, intensive care unit admission, and mortality within the ≥ 65 years population. Seasonal differences in clinical burden were linked to differences in circulating strains | ||
| 520 | |a CONCLUSIONS: Influenza exerts a considerable burden on adults aged ≥ 65 years and healthcare systems, with high incidence of hospitalization and mortality. Substantial influenza-associated clinical burden persists despite increasing vaccination coverage among adults aged ≥ 65 years across regions included in this review, which suggests limited effectiveness of currently available seasonal influenza vaccines. To reduce influenza-associated clinical burden, influenza vaccine effectiveness must be improved. Next generation vaccine production using mRNA technology has demonstrated high effectiveness against another respiratory virus-SARS-CoV-2-and may overcome the practical limitations associated with traditional influenza vaccine production | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Burden of disease | |
| 650 | 4 | |a Hospitalization | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Older adults | |
| 650 | 4 | |a Strain | |
| 650 | 4 | |a Vaccination | |
| 650 | 4 | |a mRNA vaccine | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 700 | 1 | |a Welch, Verna L |e verfasserin |4 aut | |
| 700 | 1 | |a Moran, Mary M |e verfasserin |4 aut | |
| 700 | 1 | |a Cane, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez, Santiago M C |e verfasserin |4 aut | |
| 700 | 1 | |a Srivastava, Amit |e verfasserin |4 aut | |
| 700 | 1 | |a Enstone, Ashley L |e verfasserin |4 aut | |
| 700 | 1 | |a Sears, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Markus, Kristen J |e verfasserin |4 aut | |
| 700 | 1 | |a Heuser, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Kewley, Rachel M |e verfasserin |4 aut | |
| 700 | 1 | |a Whittle, Isabelle J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d 1990 |g 40(2023), 4 vom: 15. Apr., Seite 1601-1627 |w (DE-627)NLM085859427 |x 1865-8652 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g number:4 |g day:15 |g month:04 |g pages:1601-1627 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12325-023-02432-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |e 4 |b 15 |c 04 |h 1601-1627 | ||